

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representations as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of the announcement.

INTERNATIONAL BUSINESS SETTLEMENT HOLDINGS LIMITED

國際商業結算控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 00147)

VOLUNTARY ANNOUNCEMENT

**LETTER OF INTENT FOR POSSIBLE CAPITAL INJECTION AND
INTRODUCTION OF AN INVESTOR INTO A SUBSIDIARY**

This announcement is made by International Business Settlement Holdings Limited (the “**Company**”) on a voluntary basis.

The board of directors of the Company is pleased to announce that on 12 May 2023 (after trading hours), (i) Hong Kong Unicon Optical Co., Limited (香港優你康光學有限公司), an indirectly non wholly-owned subsidiary of the Company (“**HK Unicon**”); (ii) Fujian Unicon Optical Co., Ltd (福建優你康光學有限公司) (“**Fujian Unicon**”), a direct wholly-owned subsidiary of HK Unicon; and (iii) Eyebright Medical Technology (Beijing) Co., Ltd. (愛博諾德(北京)醫療科技股份有限公司), a company listed on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (Stock Code: 688050) (“**Eyebright Medical**”) (the “**Parties**”) entered into a non-legally binding letter of intent (the “**Letter of Intent**”), pursuant to which Eyebright Medical intend to inject capital of not more than RMB100 million into Fujian Unicon (the “**Possible Capital Injection**”).

Within 30 days from the date of the Letter of Intent (the “**Exclusivity Period**”), without prior written consent of Eyebright Medical, the shareholder, directors and any other affiliates of Fujian Unicon shall not directly or indirectly communicate, discuss or negotiate with any third party in relation to the Possible Capital Injection or similar matters, or enter into any related written agreements. During the Exclusivity Period, Fujian Unicon shall notify Eyebright Medical immediately upon being approached by any potential investors.

Save for the provisions on governing law and dispute resolution, exclusivity, confidentiality and transaction fees and taxes, the Letter of Intent does not constitute a legally binding commitment between the Parties.

The Letter of Intent shall be terminated on the earlier of (i) the date on which a formal agreement in relation to the Possible Capital Injection is executed; or (ii) four months from the date of the Letter of Intent.

The Possible Capital Injection by Eyebright Medical does not only provide Fujian Unicon with financial support for its operations and development, but also plays a positive role in promoting its research and development and production of contact lenses as well as enhancing its market competitiveness, which is in line with the development strategy of the Company.

If the Possible Capital Injection materialises, it may constitute a notifiable transaction of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Further announcement(s) will be made by the Company in accordance with all applicable requirements of the Listing Rules as and when appropriate.

As the Letter of Intent is not legally binding, the Possible Capital Injection may or may not proceed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
International Business Settlement Holdings Limited
Yuen Leong
Executive Director

Hong Kong, 12 May 2023

As at the date of this announcement, the Board comprises Mr. Yuen Leong and Mr. Chan Siu Tat as executive directors; Mr. Liu Yu as non-executive director; and Mr. Yap Yung, Ms. Chen Lanran and Mr. Wong Kin Ping as independent non-executive directors.